



ASX ANNOUNCEMENT

Starpharma Presents at Macquarie Investor Event

Melbourne, Australia; 31 August 2011: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of two healthcare companies presenting at the Macquarie Bank Australia and New Zealand Annual Corporate Day in Hong Kong and Singapore.

Commencing today, the presentation to institutional investors from the Asia region will include 33 companies from Australia, from either the top 50 or 200 ASX listed companies. Starpharma and Mesoblast are the only two healthcare companies invited to present. Other companies include Amcor, Computershare, Oil Search and Westfield.

Starpharma's investment profile continues to grow in the region with a number of Asian funds now on the share register. Starpharma Chief Executive Officer Dr Jackie Fairley will also meet with a number of funds including several existing Asian institutional investors during her visit to the region.

Dr Fairley's presentation will detail recent developments in Starpharma's clinical trial program including progress with VivaGel[®] as both a treatment and preventative product for bacterial vaginosis, partnering activities including the recent deal with Ansell, and development plans for new internal programs including agrochemicals and drug delivery.

A copy of Dr Fairley's presentation is attached.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KGaA.

The Company's lead pharmaceutical development product is VivaGel[®] (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV, genital herpes and bacterial vaginosis. Starpharma has a licence agreement with Ansell Limited to develop a VivaGel[®]-coated condom, and a licence agreement with Okamoto Industries Inc in relation to the VivaGel[®]-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Siemens Healthcare as well as many research collaborations with some of the world's leading organisations in the fields of pharmaceuticals, drug delivery, cosmetics and agrochemicals.

A dendrimer is a type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). Starpharma's ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies.

FOR FURTHER INFORMATION		
Media: Buchan Consulting Rebecca Wilson Mob: +61 417 382 391 rwilson@bcg.com.au	Starpharma: Dr Jackie Fairley Chief Executive Officer +61 3 8532 2704	Ben Rogers Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



Starpharma Holdings Limited

ASX:SPL

OTCQX:SPHRY

Corporate Overview

Macquarie Corporate Day – Hong Kong

1 September 2011

Dr. Jackie Fairley CEO



This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Certain VivaGel studies are funded by U.S. NIH/NIAID/DAIDS, Contract No. HHSN266200500042C. The content of this presentation does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.



Starpharma Holdings Limited - ASX:SPL

Investment Summary

➤ **Two attractive commercial partnerships for VivaGel® coated condom:**

- VivaGel®-coated condom partnered with Ansell (#2 globally) and Okamoto, market leader in Japan

➤ **Lead product VivaGel® in advanced clinical development:**

1. VivaGel® for Bacterial Vaginosis (BV)
 - BV Treatment: VivaGel® shown to be efficacious in Phase 2; Phase 3 planned
 - BV Recurrence prevention Phase 2 underway
 - Phase 3 Trial for BV Treatment planned 2011/12

2. Microbicide Gel for HIV/HSV2/HPV prevention (sexually transmitted infections) in Phase 2

➤ **Multiple partnerships for SPL's dendrimers and active BD program:**

- Drug delivery deals (announced): **Lilly, GSK, Elanco**
- Medical technology deals: **Siemens, Aldrich, Merck, Qiagen**
- Multiple Agrochemical partnerships, including with multi-billion dollar US Co.
- Internal programs in Drug Delivery (docetaxel) and Agrochemicals

19 Aug 2011

ASX Code	SPL
Share Price SPL AUD	\$1.10
52 Week Range AUD	48c-\$1.69
Shares on Issue	247.8M
Market Capitalisation AUD	~\$272M
Average Mthly Volume: ASX	~ 15.5M shares
Cash (AUD) 30/6/11	\$18.9M
Major Shareholders	Acorn, Orbis Dow





Dendrimers – A Highly Versatile, Proprietary “Platform” Technology

Starpharma’s dendrimers are highly branched polymers with versatile commercial applications

Starpharma’s dendrimer platform has enabled it to develop:


- *an impressive list of commercial partnerships*
- *Several, well advanced, independent potential revenue streams*
- *An extensive patent portfolio (~100 granted patents)*

“Dendrimers have numerous potential applications in healthcare and industry. We see the possibility of lucrative licensing deals from dendrimer projects focused on drug delivery, animal health, agro-chemicals and many more”

Southern Cross Equities, 1 Feb 2011

“The numerous commercial options make Starpharma one of the most exciting biotech companies listed on the ASX.”

Shaw Stockbroking, 3 March 2011





Starpharma's Commercial Partnerships

Starpharma's aim is to partner with market-leading companies



VivaGel® Condom coating

Commercial partnerships with Ansell and Okamoto (in Japan)



GlaxoSmithKline



Dendrimers for Drug Delivery

Lilly, Elanco, GSK (Stiefel); Drug delivery collaborations

ELANCO

*Multibillion dollar US
Agrochemical company*

Dendrimers for Agrochemicals

SIEMENS

Stratus CS®

Various diagnostics licensed to Siemens Healthcare (Dade Behring)



SuperFect®

Gene transfection technology licensed to Qiagen



Starburst®

Dendrimers commercially available via Sigma Aldrich



Priofect® : siRNA & DNA transfection reagents



Starpharma's potential commercial returns

Starpharma aims to generate a series of parallel revenue streams

Product/Application	Indication/ Product	Commercial Strategy/ Partnering Status	Market Potential USD /Revenue model
1. VivaGel® for Bacterial Vaginosis	1. <u>BV treatment</u> Phase 3 planning 2. <u>Prevention of recurrence</u> Phase 2	License at late stage	1. BV Treatment: US\$300-350M ¹ 2. Recurrence market est. >\$1Bi
2. VivaGel® (STI)	STI (HIV/HSV2/HPV) Prevention Phase 2	License at late stage	\$3-6Bi ¹
3. VivaGel® Coated Condom	Pre-coated antiviral condom	Partnered with Ansell and Okamoto (Japan)	\$1.1 - \$1.7 Bi ¹
4. Drug Delivery	Multiple	Multiple Partnered (Lilly, GSK, Elanco, undisclosed) Internal: Docetaxel	Undisclosed/Partner Funded research/downstream returns
5. Agrochemicals and Industrial	Multiple	Multiple Partnered Programs; Multi-billion dollar US based partner, undisclosed Internal: glyphosate, others.	Undisclosed/Partner Funded research/downstream returns



VivaGel® - 2 Products: Anti-viral Condom Coating and Microbicide Gel

VivaGel®-Coated Condom



VivaGel®



Condom coated with patented antiviral
- inactivates viral STIs
(HIV, Herpes, HPV)



Licensed to
Ansell &
Okamoto (Japan)

Combination Product
(Device Branch review)



Topical Microbicide Gel
1. Bacterial Vaginosis
2. Prevention of viral
STIs (HIV, Herpes, HPV)

In-house development,
late stage license

Standard Pharmaceutical;
FDA Fast Track



VivaGel® Condom Coated Partnerships


Ansell Limited (ASX:ANN) and Okamoto Industries (TSE)

Partnership Structure:

- royalties on VivaGel® coated condom sales
- Development/registration assistance, milestones
- Enhancement of VivaGel® brand

Partner	Market Position
Okamoto TSE (Japan)	<ul style="list-style-type: none"> • No. 1 in Japan for condom sales (No. 4 globally) • ~60% Japanese market (est. \$500M) • Strong positions in Korea, Taiwan, Malaysia, Singapore, China.
Ansell Limited ASX:ANN	<ul style="list-style-type: none"> • No. 2 globally in condom sales • ~20% global share • No. 1 in Australia, strong and growth in China, Brazil, India

Global Condom Market ^
 Total Sales: US\$3.26Bi^
 Branded: US\$1.1-1.6Bi
 Growth: 4-5% annually






source: "Condoms - a global strategic business report 2006, 2010", Annual Reports and industry data.

Condoms represent a US\$3.26B market; Branded condoms ~\$1.1B

VivaGel® Condom Coated Partnerships

Ansell Limited (ASX:ANN) and Okamoto Industries (TSE)

Partner	Market Position/Share	Major Brands
<u>Okamoto Industries</u> TSE	<ul style="list-style-type: none"> No. 1 in Japan with ~60% Japanese market (the 2nd largest condom mkt. Est. ~US\$500M) No. 4 globally; strong positions in Korea, Taiwan, Malaysia, Singapore, China Total company revenues >USD 760M 	Skinless®  003® 
<u>Ansell Limited</u> ASX:ANN	<ul style="list-style-type: none"> No. 2 globally for condom sales 20% global share of branded market ~\$1.1Bi No. 1 in Australia; Strong growth in USA, China, Brazil, India and Eastern Europe. Condom business growing ~18% 	Lifestyles®  SKYN®  ZERO®  Manix® 

source: "Condoms - a global strategic business report 2006", Annual Reports and industry data.

Global Branded condom market est. \$1.1-1.6Bi; growing 4-5% pa



VivaGel® - Bacterial Vaginosis (BV) –Treatment and Prevention of Recurrence

An Attractive Commercial Opportunity

- The most common vaginal infection worldwide
- 21 million women (~29% women aged 14-49) infected in US, (up to 51% in certain demographics)
- Causes unpleasant discharge, increased risk STIs, linked to preterm birth
- Global market for ***topical*** BV treatments alone: approx. US\$300-350M
- Shortcomings amongst current antibiotic treatments:
 - Low cure rates < 50% and high rate of recurrence
 - Adverse effects: toxicity, reaction with alcohol, incompatibility with condoms
- Clinical trials showed BV resolution with VivaGel®
- Lab tests show desirable differential action between normal flora (*Lactobacilli spp.*) & pathogenic bacteria (*G. vaginalis*, *Bacteroides*, *Prevotella.*)



VivaGel® - Bacterial Vaginosis (BV) – An attractive Commercial Opportunity

Treatment and Prevention of BV Recurrence – 2 separate market opportunities

Indication	Current Market/est.	Existing therapies	Stage of Development	Commercial Strategy
Bacterial Vaginosis Treatment	US \$300-350M (topical agents alone)	Metronidazole Clindamycin (antibiotics)	<ul style="list-style-type: none"> Phase 2 trial complete Phase 3 trial Est. 2H 11 	Late stage Licence
Prevention of BV recurrence	Significantly larger than treatment: Est. > US\$1 Bi.	None approved	Phase 2 Trial commenced Aug. 11 (n~200)	Late stage Licence

Benefits of VivaGel® :

Locally acting, not systemically absorbed, selective micro. effect, compatible with latex condoms, lack of toxicity (associated with antibiotics)



VivaGel® - Bacterial Vaginosis (BV) Treatment Phase 2 Trial (n=132)

VivaGel® Phase 2 Trial meets Endpoints; announced May 2011

Assessment	Time Point	3% SPL7013 Gel	1% SPL7013 Gel	0.5% SPL7013 Gel	Placebo Gel
Clinical Cure [^]	EOT (2-5d post Rx)	63% ** (P=0.0015)	74% ** (P=0.0002)	55% ** (P=0.0098)	22%
	TOC (2-3 wks post Rx)	28% (P=0.1583)	46% ** (P=0.006)	23% (P=0.2478)	12%

Key Trial Findings:

- VivaGel® efficacy met study endpoints, comparable efficacy with conventional antibiotics (35-65%)
- VivaGel rapidly (1-4d) resolved symptoms of BV : discharge (89%) and odour (78%)
- VivaGel® well tolerated , Patient satisfaction very high:
 - 83% *extremely satisfied/very/satisfied* * vs. 35% for placebo
- Trial results support new patent filing; extends VivaGel® protection to at least 2031
- Planning for Phase 3 well advanced; est. late 2011

** Statistically significant result compared with placebo

[^]No abnormal discharge, and ≤ 1 other Amsel's criteria

*1% SPL7013



Advantages of VivaGel[®] over existing BV treatments

Advantages	VivaGel [®]	Metronidazole Tablets	Metronidazole Gel, 0.75%	Clindamycin Cream, 2%
Active Ingredient Not Carcinogenic [†]	✓	✗	✗	?
Compatible with Condoms	✓	✓	✓	✗
No Systemic Absorption	✓	✗	✗	✗
Sexual Intercourse permitted during use	✓	✓	✗	✗
Compatible with Alcohol Consumption	✓	✗	✗	✓
No Other Significant Warnings / Side Effects [‡]	✓	✗	✗	✗
Antiviral Activity	✓	✗	✗	✗

[†] Metronidazole has been shown to be carcinogenic in mice and rats. Clindamycin has not been tested for carcinogenicity in long-term studies in animals but is not genotoxic or mutagenic in other nonclinical studies.


[‡] Central and peripheral nervous system effects, such as convulsive seizures and peripheral neuropathy, have been reported in patients treated with metronidazole. Use of clindamycin phosphate is associated with Clostridium difficile-Associated Diarrhoea. Sources: Flagyl[®] Oral Tablet (metronidazole) Label Information, LAB-0162-5.0, revised August 2010; Vandazole[®] Vaginal Gel (metronidazole) Label Information, Rev. C 12/2010; Clindesse[®] Vaginal Cream (clindamycin) Label Information, Revised 12/2010



VivaGel® - Microbicide for the Prevention of STIs (HPV, Herpes, HIV)

Product	<ul style="list-style-type: none"> • Topical vaginal microbicide (+ condom coating)
STI Indication:	<ul style="list-style-type: none"> • Under development: Prevention of STIs in women • Two INDS - HIV and genital herpes (HSV-2)
Presentation:	<ul style="list-style-type: none"> • Applicator delivered water based Gel
Active:	<ul style="list-style-type: none"> • Pharmaceutical grade Dendrimer (SPL7013)
Mechanism:	<ul style="list-style-type: none"> • Receptor mediated; SPL7013 Highly active in HIV, Herpes and HPV(in-vitro and in vivo); active in BV, chlamydia under investigation
Development Stage:	<ul style="list-style-type: none"> • Phase 2 ; Well tolerated in human trials (n>300) • FDA Fast Track Status
Commercial Opportunity:	<ul style="list-style-type: none"> • Industry surveys confirm strong consumer demand for STI Microbicide • 30 - 40% of female US college students would buy a Microbicide effective against STIs • Independent Microbicide market estimates US\$1.5-6 Bi

Estimated Market* for STI Microbicides in Developed Countries



Source: World Bank; UNAIDS; EC AIDS survey; BCG analysis, various analyst and microbicide publications;

*Key assumptions: 291m women of reproductive age (15-49) in developed countries Unit sale price ~ US\$2; Usage rates according to published data



VivaGel[®]: Human Papilloma Virus (HPV) Activity

VivaGel[®] has broad activity in HPV strains not currently addressed by existing vaccines

	HPV-5	HPV-6	HPV-11	HPV-16	HPV-18	HPV-31	HPV-45
Genital warts Cutaneous infection		✓	✓				
Cervical Carcinoma				✓	✓	✓	✓
Gardasil[®] (CSL/Merck)	✗	✓	✓	✓	✓	✗	✗
Cervarix[®] GSK	✗	✗	✗	✓	✓	✗	✗
VivaGel[®] SPL7013*	✓	✓	✓	✓	✓	✓	✓


*In-vitro results obtained at NCI and University of Queensland



Dendrimers for Drug Delivery

Advantages include – reduced toxicity, less frequent dosing and new patents

Attached Drug Molecule



Capabilities of Starpharma's Technology include:

- Product lifecycle management (extend patent life)
- Improved efficacy of drugs
- Extension of drug half-life
- Reduced toxicity
- Active or passive targeting (e.g. EPR*)
- Improved solubility of drugs
- Drug "rescue"

**enhanced permeability & retention effect*

Starpharma's Delivery Partnerships:


- Eli Lilly and Company – human pharmaceuticals
- Stiefel Labs. Inc (a GSK company) – Dermal
- Lilly's Animal Health Division , Elanco
- Various additional, early stage





Dendrimers for Drug Delivery - Proteins and Peptide Drugs

Longer half life – less frequent dosing



Approach

Conjugate protein or peptide to functionalised dendrimer

Benefit

Control half life of protein or peptide therapeutics

Improve dosing regimen


Reduce protein metabolism

Status

in vivo using insulin for proof of concept **achieved**

Co-development program with undisclosed partner

In vivo mouse model




Dendrimer insulin shows prolonged suppression of blood glucose *in vivo*





Dendrimers for Drug Delivery

Efficacy - with reduced toxicity

Cardiac toxicity of one of world's most widely used cancer drugs (doxorubicin) reduced markedly



Mouse Tissue Deposition



...whilst preserving or enhancing drug function



Drug Delivery: Potential to create significant value

Examples of companies which have created value through drug delivery



Company	Valuation	Therapeutic Focus	Value driver
Abraxis Bioscience Nasdaq: ABII ^	US\$2.9Bi ^Acquired by Celgene June 2009	Oncology	Abraxane : global sales >USD 300M. (a nanoparticle, Water soluble formulation of paclitaxel) Wider application to other therapies
Nektar Therapeutics Nasdaq: NKTR	US\$1.35Bi (Market Capitalisation)	Oncology CNS Autoimmune Anti-infective Other	Pipeline and portfolio of novel products based on polymer delivery platform Partnerships with top tier biopharmaceutical companies



Paclitaxel (Taxol®) & water



Paclitaxel-Dendrimer
Water solubility > 9000x greater



Dendrimers for Drug Delivery

Lead Candidate: Docetaxel

- Docetaxel (Taxotere® - Sanofi Aventis) is used to treat breast, lung and prostate cancer (US\$3Bi, 2010)
- Starpharma Technology has enabled dramatic improvement in solubility (2,000 – 8,000 fold)
- Solubility enhancements potentially enabling development of novel improved formulations with forecast reduction in toxicity
- New formulation may not require premedication with high doses of cortisone
- Improved Docetaxel analogous to reformulated Abraxane (nanoparticle water soluble form of paclitaxel) US\$ 300M in 2009
- New patent filed incorporating recent docetaxel data





Top ten Injectable Cytotoxics – 2009

Brand	Molecule	Innovator Company	2009 Sales (\$ M USD)
Taxotere	Docetaxel	Sanofi Aventis	2,140
Eloxatin	Oxaliplatin	Sanofi Aventis	1,484
Alimta	Pemetrexed	Eli Lilly	1,306
Gemzar	Gemcitabine	Eli Lilly	1,107
Doxil/ caelyx	Pegylated doxorubicin	JnJ / Merck	384
Camptosar	Irinotecan	Pfizer	329
Abraxane	Albumin bound paclitaxel	Celgene	310
Vidaza	Azacitidine	Celgene	299
Taxol	Paclitaxel	BMS	292
Treanda	Bendamustine	Cephalon/ Astellas	241



Dendrimers in Agrochemicals



Starpharma signs agrochemicals deal

Melbourne, Australia; 5 November 2009 - Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a research and collaboration agreement between its wholly owned US subsidiary, DNT Inc, and a prominent, US-based agricultural chemicals company. The confidentiality provisions of the agreement prevent disclosure of the name of the collaborating company at this time.

Under the agreement the parties will use DNT's Priostar® dendrimer technology to enhance the performance of existing pesticides. The approach is a natural extension of Starpharma's drug delivery work, in which dendrimers extend the persistence of an active molecule, potentially reducing the amount of active that is required for a given effect.

The agreement applies to specific classes of pesticides, and does not prevent Starpharma's further commercialisation of dendrimers more widely in the agricultural chemicals sector.

- Extension of drug delivery technology
- Valuable new opportunity for dendrimers
- Agrochemicals market US\$124B (Pesticides US\$35.8B)
- Faster development than pharmaceuticals
- One agreement announced Nov. 2009 – a number of discussions in progress



Model demonstrating multiple points of attachment

Dendrimer can enhance the performance of existing agrochemicals

- Adhesion to difficult surfaces
- Extension of effect/
Controlled release
- Solublising
- Protection of Actives
- Sequestration



Dendrimers in Agrochemicals – generics offer a number of attractive candidates

Program involves applying SPL's dendrimer technology to various generic agrochemical agents

Leading Generic Agrochemicals[#]

Active Ingredient	Activity	Market Value (\$M USD)
Glyphosate	Herbicide	5000
Imidacloprid	Insecticide	1000
Acephate	Insecticide	350
Pendimethalin	Herbicide	350
Acetochlor	Herbicide	300
Chlorpyrifos	Insecticide	300
Trifluralin	Herbicide	300

ASX ANNOUNCEMENT

Starpharma to expand agricultural program through \$250,000 funding

Melbourne Australia; Thursday 3rd March 2011– Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) has been awarded \$250,000 funding to enhance agrochemicals using its Priostar[®] dendrimers.

The funding, announced last night by the Minister of Technology, Gordon Rich-Phillips, as part of the Victorian Government's Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates.

Starpharma will be applying its Priostar[®] dendrimer technology to improve delivery of agrochemicals to enable healthier plant growth and fight plant disease. As well as increasing efficacy, improved delivery control of chemicals can reduce both the frequency of application and amount applied. Such innovations have the potential to reduce farmers' costs and also reduce environmental impact.



Dendrimers in Agrochemicals

Initial Results: Improvement of Glyphosate and other actives

Starpharma's initial results - announced July 2011:

- Glyphosate (e.g. **Roundup**[®]) effectiveness measured using "brownout" (rate of vegetation dying off)
- Starpharma's dendrimers improved performance of glyphosate by ~160-320% compared to glyphosate alone
- Glyphosate market is US\$5BN globally

Additional work also undertaken on key actives including:

- Imidacloprid (e.g. Confidor[®]) globally US\$1 Bi
- Trifluralin (e.g. Treflan[™]) globally US\$300 M

Other results include:

- solubility enhancement
- Modification of soil penetration properties




Photo depicting "brownout"



Starpharma's potential commercial returns

Starpharma aims to generate a series of parallel revenue streams

Product/Application	Indication/ Product	Commercial Strategy/ Partnering Status	Market Potential USD /Revenue model
1. VivaGel® for Bacterial Vaginosis	1. <u>BV treatment</u> Phase 3 planning 2. <u>Prevention of recurrence</u> Phase 2	License at late stage	1. BV Treatment: US\$300-350M ¹ 2. Recurrence market est. >\$1Bi
2. VivaGel® (STI)	STI (HIV/HSV2/HPV) Prevention Phase 2	License at late stage	\$3-6Bi ¹
3. VivaGel® Coated Condom	Pre-coated antiviral condom	Partnered with Ansell and Okamoto (Japan)	\$1.1 - \$1.7 Bi ¹
4. Drug Delivery	Multiple	Multiple Partnered (Lilly, GSK, Elanco, undisclosed) Internal: Docetaxel	Undisclosed/Partner Funded research/downstream returns
5. Agrochemicals and Industrial	Multiple	Multiple Partnered Programs; Multi-billion dollar US based partner, undisclosed Internal: glyphosate, others.	Undisclosed/Partner Funded research/downstream returns



Investment Summary and Financials

- Starpharma has:*
- *A highly versatile, proprietary technology platform with extensive patent portfolio*
 - *An impressive list of existing commercial partnerships and an active ongoing commercialisation effort*
 - *Near term commercial and clinical milestones*
 - *Several well advanced potential revenue streams*
 - *A sound financial position and experienced management team*

	FY 2011 AUD \$M
Total revenue and income	3.3
Net loss after tax	8.9
Cash outflow from operations	(6.5)
Net share capital proceeds	3.6
Net cash burn for the year	(3.9)
Cash at bank (30/6/11)	18.9

